Simulations Plus Clears Key Antitrust Hurdle in Altaris Buyout
Simulations Plus says the HSR antitrust waiting period has expired, clearing a major regulatory condition for its pending acquisition by Altaris.
Simulations Plus, Inc. (Nasdaq: SLP) announced Tuesday that the mandatory antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired without challenge, removing a critical regulatory barrier to its pending acquisition by private investment firm Altaris, LLC.
The HSR waiting period is a standard federal requirement that gives the Department of Justice and Federal Trade Commission time to review proposed mergers for potential competitive harm. Its expiration without government intervention signals that regulators found no antitrust objections to Altaris taking control of the North Carolina-based drug development software company.
Read more Tim Cook and Howard Lutnick Open Apple Plant in Houston →
Simulations Plus describes itself as a global leader in model-informed and AI-accelerated drug development, providing technology and services that advance biopharma innovation. The company's computational modeling tools are widely used across the pharmaceutical industry to streamline drug discovery and regulatory submissions.
While the HSR clearance satisfies one of the required regulatory conditions for closing, the transaction still has additional conditions to fulfill before the deal can be completed. The companies have not announced a revised closing timeline in connection with this update.
The deal represents a significant move for Altaris to deepen its footprint in life sciences technology at a time when AI-driven drug development platforms are attracting growing investor interest across the biopharma sector. Continue reading at BusinessWire.
